| abstract |
The present invention is bladder cancer, colon cancer, liver cancer, lung cancer, breast cancer, vaginal cancer, ovarian cancer, pancreatic cancer, kidney cancer, gastrointestinal cancer, gastrointestinal cancer, prostate cancer, head and neck cancer, peritoneal cancer, thyroid cancer, bone cancer, brain cancer, central nervous system cancer and / Or 5- (2,4-dihydroxy-5-iso) for the treatment of blood cancer and / or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multiple Castleman disease and / or psoriasis Propyl-phenyl) -4- (4-morpholin-4-ylmethyl-phenyl) -isoxazole-3-carboxylic acid ethylamide or tautomers thereof or pharmaceutically acceptable salts or hydrates or solvates thereof will be. |